Samsara BioCapital is a healthcare investment manager in Palo Alto, California, whose stated purpose on its own homepage is "Investing to create transformative therapeutics for patients." Its Culture page states that the firm takes "a long term, patient, company-build perspective" and that it will "provide capital through a company's full risk cycle and over many years, whether the company is private or public", that its people actively engage as board members, that it uses data-driven decision making, and that unmet medical need and patient benefit are its guiding principles. The firm accordingly runs both private and public-company strategies: it is an SEC-registered investment adviser (SEC number 801-113741) and files quarterly Form 13F-HR reports on its US-listed long positions, and its investment team includes a Principal, Public Investing. The homepage states that the firm brings together "scientists, physicians, drug developers, and business leaders with over 500 years of combined experience to back the next generation of therapeutic breakthroughs." The firm publishes no stage, cheque-size or geographic mandate of its own, so none is recorded here.
Samsara BioCapital, L.P. is organised in Delaware and files its first Form D on 21 March 2017 for a $300,000,000 venture capital fund offering, naming Samsara BioCapital GP, LLC, Srinivas Akkaraju and Michael Dybbs as related persons; the filing records the first sale as yet to occur.
2017
First sale in the fund occurs on 22 March 2017, per the later Form D/A.
2018
Form D/A filed 20 April 2018 reports the Samsara BioCapital, L.P. offering at $310,090,000 with $310,090,000 sold and nothing remaining. This is a fund close, not an AUM figure.
2019
The firm files its first Form 13F-HR on 14 February 2019, covering the quarter ended 31 December 2018, beginning its public-equity reporting history.
2020
A further Form D is filed on 31 December 2020 under the same Samsara BioCapital, L.P. entity for a $500,000,000 offering, recorded with no sales at the time of filing.
2022
Scholar Rock announces on 26 July 2022 that Srinivas Akkaraju, M.D., Ph.D. has joined its Board of Directors.
2026
Form 13F-HR for the quarter ended 30 June 2026, filed 14 August 2026, reports 24 positions with a total value of $1,217,462,122.